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OBJECTIVES This study was designed to compare the prognostic value of an abnormal troponin level
derived from studies of patients with non-ST elevation acute coronary syndromes (ACS).
BACKGROUND Risk stratification for patients with suspected ACS is important for determining need for
hospitalization and intensity of treatment.
METHODS We identified clinical trials and cohort studies of consecutive patients with suspected ACS
without ST-elevation from 1966 through 1999. We excluded studies limited to patients with
acute myocardial infarction and studies not reporting mortality or troponin results.
RESULTS Seven clinical trials and 19 cohort studies reported data for 5,360 patients with a troponin T
test and 6,603 with a troponin I test. Patients with positive troponin (I or T) had significantly
higher mortality than those with a negative test (5.2% vs. 1.6%, odds ratio [OR] 3.1). Cohort
studies demonstrated a greater difference in mortality between patients with a positive versus
negative troponin I (8.4% vs. 0.7%, OR 8.5) than clinical trials (4.8% if positive, 2.1% if
negative, OR 2.6, p 5 0.01). Prognostic value of a positive troponin T was also slightly
greater for cohort studies (11.6% mortality if positive, 1.7% if negative, OR 5.1) than for
clinical trials (3.8% if positive, 1.3% if negative, OR 3.0, p 5 0.2)
CONCLUSIONS In patients with non-ST elevation ACS, the short-term odds of death are increased three- to
eightfold for patients with an abnormal troponin test. Data from clinical trials suggest a lower
prognostic value for troponin than do data from cohort studies. (J Am Coll Cardiol 2001;38:
478–85) © 2001 by the American College of Cardiology
Patients with acute coronary syndromes (ACS) have varying
levels of risk for suffering unfavorable outcomes such as
death, myocardial infarction (MI) or other major cardiac
complications. Despite development of various diagnostic
approaches, the evaluation of patients with chest pain
suggestive of acute myocardial ischemia remains a common,
costly problem, with approximately five million people
undergoing evaluation in emergency departments annually
in the U.S. at an estimated cost of more than $6 billion (1).
Patients with chest pain and ST-segment elevation on a
standard electrocardiogram (ECG) can be quickly identified
as having substantially increased risk and be considered for
immediate reperfusion therapy based on current guidelines
(2). Patients without ECG evidence of ST elevation or new,
pathologic Q-waves are more difficult to assess, especially
concerning the risk of short-term adverse events. This
uncertainty can lead to unnecessary hospital admissions
(often for intensive monitoring) as well as a few inappro-
priate discharges from the emergency department of pa-
tients with a high risk of MI or death (3). Indeed, among
patients diagnosed with unstable angina, only 6% to 15%
have a short-term risk of cardiac events low enough to be
discharged home safely, on the basis of recent guidelines (4).
Prospective studies of troponin assays in ACS have
demonstrated that troponin T and I have diagnostic accu-
racy comparable with, if not better than, creatine
kinase-MB (5–7) and also predict long-term risk for adverse
cardiac events (8–13). However, interpretation of the ag-
gregate data to date is hampered by heterogeneity in the
patient populations to which the tests have been applied. To
provide a better overall assessment of the prognostic values
of cardiac troponin T and I, we systematically reviewed
published studies evaluating these markers in patients with
non-ST elevation ACS. We wished to compare prognostic
value of an abnormal troponin obtained from clinical trials
with the prognostic value obtained from cohort studies
enrolling consecutive patients.
METHODS
Data sources and study selection. We searched MED-
LINE (1966 to 1999) and reviewed cited references of
retrieved articles to identify relevant published studies. Our
search criteria were: 1) the text word “troponin,” and 2) the
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text words “angina,” “unstable,” “myocardial infarction” or
“ischemia.” We also performed a search of the EMBASE
database from 1990 to 1998, but did not find any additional
articles fulfilling the study criteria. We contacted experts in
the field of cardiac markers to identify large unpublished
cohort studies.
We restricted our review to clinical trials and cohort
studies that evaluated patients with suspected myocardial
ischemia. We excluded studies that included only patients
with MI. We also excluded case-control studies, articles that
did not report mortality and studies published in a language
other than English. We excluded studies that included
patients with ST-elevation MI unless the studies reported
separate data on patients with non-ST-elevation MI (13).
Study selection was performed initially by title review
(P.A.H.). Candidate abstracts were then reviewed and
selected for data retrieval. Two independent reviewers
abstracted data for each article on standardized electronic
data forms. A third reviewer compared their results and
settled any differences. In general, at least one reviewer of
the pair had clinical cardiology expertise and one had
experience in critical appraisal. We recorded the outcome of
death for all studies, and the combined end point of death
or MI for studies including patients with unstable angina. If
outcomes at more than one time period were reported, we
used the value closest to 30 days following presentation.
We prespecified comparisons of studies enrolling patients
with suspected ischemia versus studies enrolling patients in
whom MI had already been excluded (unstable angina). We
also compared studies of troponin T versus studies of
troponin I, studies of troponin T using early-generation
tests (threshold 0.2 ng/ml) and those using a more recent
test (threshold 0.1 ng/ml) for troponin positivity. We chose
to examine cohort studies and clinical trials separately
because the included patients are often different. Cohort
studies typically include consecutive patients, whereas clin-
ical trials include a more defined population.
Statistical analysis. We used standard random
(DerSimonian-Laird) and fixed (Peto) effects methods to
estimate summary odds ratios (ORs) for the outcomes of
death and MI (14,15). Because both fixed and random-
effects summary estimates were similar, we report only the
random-effects results. For studies with no events in a
patient group, we substituted 0.5 in place of 0 for the
random effects calculation. We tested homogeneity of study
effect size using the Q statistic (15). We examined differ-
ences between study subgroups using analysis of variance
(16). Data are presented as summary ORs with 95%
confidence intervals, with two-tailed p values and statistical
significance set at p , 0.05.
RESULTS
Study selection. A total of 33 articles were identified by
the MEDLINE search and citation review. We excluded
four studies that may have fit the inclusion criteria but were
not written in English (17–20). Two studies (21,22) were
excluded because they reported duplicate information in-
cluded in other studies. The remaining 27 articles from 26
studies (one study reported troponin T [13] and I [23] in
separate reports) were abstracted (9–13,23–44). Eight re-
ports from seven clinical trials (9,13,23,24,27,35,36,42) and
19 cohort studies (10–12,23,25,26,28–34,37–41,43,44) of
consecutive patients included a total of 5,360 patients with
a troponin T test and 6,603 with a troponin I test.
Patient and study characteristics. The mean age of en-
rolled patients was 63 years; 67% were men and 36% had a
history of MI. A history of hypertension was noted in 42%,
diabetes in 17% and smoking in 41% (Table 1). The
included studies had a median follow-up of 12 weeks (mean
24 weeks). Five of 26 studies compared troponin T and I
directly. Thus, there were 31 evaluations of troponin T or I.
Seventeen studies of troponin T (Table 2) and 10 studies of
troponin I (Table 3) reported mortality. There were an
additional two studies of troponin T and two of troponin I
that reported only the combined end point of subsequent
MI or death (Tables 2 and 3).
Overall, patients with a positive troponin (I or T) had
significantly worse outcomes than patients with a negative
troponin. The mortality in patients with a positive troponin
was 5.2%, compared with the mortality in patients with a
negative troponin of 1.6%, yielding an OR for death of 3.1
(95% confidence interval [CI]: 2.3 to 4.1). Because the
overall mortality was low the OR approximates the relative
risk for mortality. A positive troponin was also associated
with a significantly greater risk of death or MI: 13.5% versus
5.9%, OR 2.5 (95% CI 2.0 to 3.1).
Clinical trials versus cohort studies. The proportion of
troponin-positive patients was higher in clinical trials than
in cohort studies, but their mortality rate was significantly
lower (Table 4). In contrast, the mortality rate of troponin-
negative patients was similar in the clinical trials and cohort
studies. Consequently, a positive troponin was associated
with a higher summary OR for mortality (Figs. 1 and 2) in
the cohort studies, both for troponin I (p 5 0.01) and for
troponin T (p 5 0.2)
Two clinical trials (both of platelet glycoprotein IIb/IIIa
receptor antagonists; one examined troponin I [27]; and the
other troponin T [35]) reported separate troponin data for
control and intervention groups. The summary OR for
mortality with a positive troponin (T or I) for patients
receiving placebo was 2.9 (1.6 to 5.12). This was signifi-
cantly higher than the OR with a positive troponin for
Abbreviations and Acronyms
ACS 5 acute coronary syndromes
CI 5 confidence interval
ECG 5 electrocardiogram
MI 5 myocardial infarction
OR 5 odds ratio
TIMI 5 Thrombolysis In Myocardial Infarction
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patients receiving the intervention (1.0, 95% CI 0.4 to 2.1,
p 5 0.03).
Troponin T versus I. When we limited the analysis to the
two trials (23,42) and two cohort studies (10,44) that
directly compared troponin T and I, there was no significant
difference between the summary OR for mortality with
troponin T (5.2, CI 3.1 to 8.5) and troponin I (3.9, CI 2.3
to 6.6, p 5 0.8).
Early troponin prognostic value. Four clinical trials
(9,13,24,35) and four cohort studies (10,32,37,39) examined
the association of an early positive troponin result (within
6 h of presentation) and subsequent mortality. All treating
clinicians were blind to the troponin results. There were
2,116 patients in clinical trials with a negative early troponin
result, of whom 29 (1.4%) died during a mean follow up of
9 6 10 (median 5) weeks. Mortality was lower among the
cohort patients (0.4%, 4/917) despite a longer mean
follow-up time of 20 6 22 (median 12) weeks. The
summary OR for mortality with an early positive troponin
was greater for the cohort studies (23.7, 95% CI 6.6 to 85.6)
than for the clinical trials (3.0, 95% CI 1.8 to 5.0, p 5 0.003
for difference between trial and cohort studies).
The mortality rate for patients with a negative initial
troponin test was greater in studies that included a high
fraction of patients with evidence of ischemia on the ECG
(Fig. 3). For the two studies including only patients with
ischemic ECG changes, the mortality for patients with an
initial negative troponin ranged from 1.6% (at 24 weeks)
(35) to 4.4% (at 4 weeks) (23).
Short versus long-term follow-up time. The odds of
death for patients with a positive troponin test were higher
for cohort studies with follow-up of ,12 weeks (11.4, 95%
CI 4.5 to 28.9) than for cohort studies with longer term
follow-up (3.2, 95% CI 1.8 to 5.5).
Rapid bedside tests. There were four studies of rapid
bedside tests (10,24,32,44). The mortality rate was 0.57%
(8/1398) for a negative bedside test and 7.3% (26/357) for a
positive test, yielding an OR for mortality of 7.8 (95% CI
2.6 to 23.1).
Troponin T test type. We compared cohort studies that
used older generation quantitative troponin T tests with
those using newer generation tests. The mortality rate for
the seven cohort studies using the older generation test
(threshold 0.2 ng/ml) was 14.6% (31/213) for a positive test
and 3.9% (23/585) for a negative test at a median 12 weeks
of follow-up. Mortality rates were lower for both positive
(2.8%, 3/108) and negative (1.0%, 4/405) troponin results
for the three cohort studies using a newer generation test
Table 1. Characteristics of the Study Populations
Author Year Age*
Men
(%)
History of MI
(%)
Hypertension
(%)
Diabetes Mellitus
(%)
Study
Design
Patient
Cohort
Troponin I
Antman et al. (9) 1996 59 67 40 42 na Trial ACS
Brscic et al. (25) 1998 62 73 46 na na Cohort ACS
Fearon et al. (29) 1999 na na na na na Cohort UA
Galvani et al. (26) 1997 66 68 48 na na Cohort UA
Heeschen et al. (27) 1999 64 69 45 54 20 Trial ACS
Janorkar et al. (28) 1999 64 79 34 56 11 Cohort ACS
Meyer et al. (30) 1998 64 64 na 45 15 Cohort ACS
Troponin T
Antman et al. (24) 1998 64 63 38 60 33 Trial ACS
de Winter et al. (31) 1996 63 61 41 na na Cohort ACS
deFilippi et al. (32) 1998 52 46 na 55 27 Cohort ACS
Gokhan Cin et al. (33) 1996 49 68 na na na Cohort UA
Hamm et al. (34) 1992 62 73 na na na Cohort UA
Hamm et al. (35) 1999 61 72 24 26 12 Trial UA
Lindahl et al. (36) 1996 70 65 29 33 13 Trial UA
Mockel et al. (37) 1998 57 69 na 59 18 Cohort ACS
Ohman et al. (13) 1996 63 69 26 51 22 Cohort ACS
Pettijohn et al. (38) 1997 na na na na na Cohort UA
Ravkilde et al. (11) 1993 68 71 49 27 9 Cohort UA
Ravkilde et al. (12) 1995 64 64 28 9 9 Cohort ACS
Rebuzzi et al. (39) 1998 64 72 na 37 11 Cohort UA
Stubbs et al. (40) 1996 61 73 36 27 16 Cohort ACS
Yang et al. (41) 1995 na 79 na na na Cohort UA
Troponin I and T
Christenson et al. (23)† 1998 63 69 26 52 21 Trial ACS
Hamm et al. (10) 1997 62 59 na na na Cohort ACS
Luscher et al. (42) 1997 64 71 49 38 15 Trial ACS
Mathew et al. (44) 1999 59 71 27 43 8 Cohort ACS
Olatidoye et al. (43) 1998 64 49 na 52 25 Cohort UA
*Mean or median; †troponin T data were previously published (13). Troponin I data used for analysis.
ACS 5 suspected acute coronary syndrome (non-ST elevation); MI 5 myocardial infarction; na 5 not available; UA 5 unstable angina (MI excluded).
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(threshold 0.1 ng/ml). All clinical trials used the new
generation quantitative troponin T test. No studies were
published using a threshold of 0.01 ng/ml.
Troponin and death or MI in unstable angina. The
prognostic value of troponin in predicting the combined end
point of death or nonfatal MI for patients with unstable
angina was greater in the cohort studies than in the
randomized trials. In the seven cohort studies (n 5 700),
death or MI occurred in 28% of troponin-positive patients
compared with 5.4% of troponin-negative patients during a
mean 11 weeks of follow-up. In the trials (n 5 3,693), death
or MI occurred in only 11.7% of troponin-positive patients
compared with 6.0% of troponin-negative patients during a
mean 16 weeks of follow-up.
DISCUSSION
This overview found that measurement of serum troponin
provides significant information about the short-term risk of
death for patients with non-ST segment elevation ACS.
Patients with a positive troponin test had a short-term risk
of death three- to eightfold higher than patients with a
negative test. However, the magnitude of risk associated
with a positive troponin was greater in cohort studies of
consecutive patients than in clinical trials. These results
were consistent across studies using troponin I or T and
those using a combined end point of death or MI.
Clinical trials versus cohort studies. There are several
possible explanations for the discrepancy in the prognostic
Table 2. Outcomes for Studies of Troponin T
Author
Definition of
Positive Troponin
Follow-Up
(Weeks)
Death/Total Troponin
Death or MI/Total*
Troponin
Positive Negative Positive Negative
Antman et al. (24) Any 2 2/116 7/481 na na
de Winter et al. (31)† Any 26 0/24 1/146 1/24 2/146
deFilipp et al. (32)† Initial 52 4/39 0/132 na na
Gokhan Cin et al. (33) Initial or second 1 6/24 2/48 na na
Hamm et al. (10)† Any 4 16/123 4/650 na na
Hamm et al. (34) Any 1 5/33 1/51 10/33 1/51
Hamm et al. (35) Any 24 9/275 10/615 46/275 52/615
Lindah et al. (36)† Any 20 13/399 0/182 51/399 8/182
Luscher et al. (42)† Any by 6 h 4 8/249 1/267 na na
Mathew et al. (44)‡ Any 12 1/31 0/183 na na
Mockel et al. (37) Any 12 1/11 2/95 na na
Ohman et al. (13) Initial 4 13/131 4/189 na na
Olatidoye et al. (43) Initial 4 na na 5/14 3/93
Pettijohn et al. (38)† Any 24 2/35 3/94 6/35 7/94
Ravkilde et al. (11)† Any 24 3/44 1/83 6/44 3/83
Ravkilde et al. (12)† Any 112 3/25 3/99 na na
Rebuzzi et al. (39) Initial 12 1/14 0/88 7/14 8/88
Stubbs et al. (40)† Initial 147 12/62 14/121 na na
Yang et al. (41) Any 1 na na 11/34 1/60
Total or mean 28 99/1,635 53/3,524 136/804 80/1,183
*In unstable angina patients; †deaths limited to those of cardiac cause; ‡data available for serum and whole-blood assays. Whole-blood assay data used for summary calculation.
MI 5 myocardial infarction; na 5 not available/applicable.
Table 3. Outcomes for Studies of Troponin I
Author
Definition of
Positive Troponin
Follow-up
(Weeks)
Death/Total Troponin
Death or MI/Total*
Troponin
Positive Negative Positive Negative
Antman et al. (9) Any 6 21/573 8/831 na na
Brscic et al. (25) Any 4 2/22 2/70 na na
Christenson et al. (23) Initial 4 26/220 24/550 na na
Fearon et al. (29) Any 28 na na 3/16 5/77
Galvani et al. (26)† Any 4 2/22 0/69 5/22 4/69
Hamm et al. (10)† Any 4 19/171 1/602 na na
Heeschen et al. (27) Any 4 25/629 36/1,593 na na
Janorkar et al. (28) Any 38 1/34 1/46 na na
Luscher et al. (42)† Any by 6 h 4 7/213 2/303 na na
Olatidoye et al. (43) Initial 4 na na 5/13 3/94
Mathew et al. (44) Any 12 1/55 0/159 na na
Meyer et al. (30) Any 24 4/42 3/199 na na
Total or mean 10 108/1,981 77/4,422 13/51 12/240
*In unstable angina patients; †deaths limited to those of cardiac cause.
MI 5 myocardial infarction; na5not available/applicable.
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value of troponin between clinical trials and cohort
studies. First, the patients recruited for trials are likely to
be more highly selected than patients from cohort studies
of consecutive patients. Unselected patient populations
are more heterogeneous and, therefore, may have greater
potential for variation in underlying prognosis than
would the more homogeneous population enrolled in a
clinical trial.
Another possible explanation for the lower risk with a
positive troponin in clinical trials is that the interventions
attenuated the prognostic value of a positive troponin by
lowering the risk of the treated patients. This is suggested
Figure 1. The odds ratio for increased mortality with a positive troponin I
for clinical trials and cohort studies. Data are displayed for each study with
at least one death in both positive and negative troponin T subgroups. The
summary odds ratio assumes random effects. Error bars represent 95%
confidence intervals.
Figure 2. The odds ratio for increased mortality with a positive troponin T
for clinical trials and cohort studies. Data are displayed for each study with
at least one death in both positive and negative troponin T subgroups. The
summary odds ratio assumes random effects. Error bars represent 95%
confidence intervals.
Table 4. Summary Results for Troponin and Mortality
Troponin T Troponin I
Clinical Trials
(n 5 5)
Cohort Studies
(n 5 12)
Clinical Trials
(n 5 4)
Cohort Studies
(n 5 6)
Total patients 2,904 2,255 4,912 1,491
Mean age (years) 64 60 63 63
Male (%) 68 66 69 69
Troponin positive (%) 40 21 33 23
Death rate troponin positive (%) 3.8 11.6 4.8 8.4
Death rate troponin negative (%) 1.3 1.7 2.1 0.7
Median follow-up (weeks) 4 18 4 8
Summary OR (95% CI) 3.0 (1.6–5.5) 5.1 (3.2–8.4) 2.6 (1.8–3.6)* 8.5 (3.5–21.1)*
Study heterogeneity p value 0.28 0.11 0.28 0.16
*p 5 0.01 for difference between trial and nontrial troponin I results; †a p value ,0.05 indicates significant heterogeneity between trials in the mortality odds ratio for a positive
troponin.
CI 5 confidence interval; OR 5 odds ratio.
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by data from c7E3 Fab Antiplatelet Therapy in Unstable
Refractory Angina (CAPTURE) (35) and Platelet Receptor
Inhibition in Ischemic Syndrome Management (PRISM)
(27) where the combined OR for a positive troponin was 1.0
for the intervention group. The Thrombolysis In Myocar-
dial Infarction (TIMI) risk score for unstable angina/
non-ST elevation MI (8) developed using cardiac marker
data from TIMI 11B (45) was also more predictive of events
for patients receiving control (unfractionated heparin) than
for those receiving low-molecular-weight heparin.
One implication of our findings is that the prognostic
ability of traditional risk factors or markers may vary
considerably between trial and non-trial studies. The rela-
tive prognostic value of different patient characteristics (such
as age or ST depression) may also differ between trial and
cohort populations. Data from CAPTURE (35), PRISM
(27) and TIMI 11B (45) indicate that the prognostic value
of troponin and other risk factors depends on the treatment
provided. Further studies are needed to determine the
prognostic value of risk factors in both trial and non-trial
settings.
Troponin versus other risk factors. The available data do
not establish the degree to which troponin testing adds to
the prognostic information conveyed by the ECG and other
clinical factors (such as diabetes, age and gender). Most
studies have examined each clinical factor in isolation rather
than in a multivariable analysis. Three recent trials (8,9,13)
and one cohort study (22) compared ECG findings, clinical
data and troponin values in predicting outcome in patients
with unstable angina or non-Q-wave MI. ST depression
was a significant predictor of cardiac events in all studies,
and troponin was an independent predictor in three studies.
The TIMI risk score (8) noted that cardiac markers (in-
cluding troponin) were independent of age, risk or severity
of coronary artery disease, recent angina, use of aspirin and
ST-segment deviation in predicting death, MI or need for
urgent revascularization. Although these studies indicate
that troponin testing provides independent prognostic in-
formation, further analyses are needed to confirm these
findings in less selected patients, and to establish the value
of this information in clinical decision making.
One of the potential benefits of risk assessment in
patients with ACS is the ability to identify candidates for
aggressive anti-ischemic therapy. Aspirin, heparin and beta-
blockers are known to be effective in patients with unstable
angina (4). Recently, new generation antiplatelet therapy
(IIb/IIIa receptor inhibitors) (46) and anticoagulants (low-
molecular-weight heparin) (45) have been shown to be more
effective than usual care. Substudies of randomized trials
have reported that patients with a positive troponin benefit
more from low-molecular-weight heparin (47), and the
platelet glycoprotein IIb/IIIa receptor inhibitors abciximab
(35) and tirofiban (27) than those with a negative troponin
test. These studies suggest that the troponin level can be
used to guide therapy for patients with non-ST elevation
ACS. However, a strategy of waiting for a positive troponin
test before starting an intervention has not been evaluated in
clinical trials.
One potential use of the troponin test is to identify
low-risk patients in the emergency department who could
be safely discharged home. In a study by Hamm et al. (10),
patients with negative troponin tests had low 30-day event
rates (0.3% for troponin I and 1.1% for troponin T). Our
findings suggest that any risk assessment cannot rely solely
on the troponin level. In studies of patients with suspected
ACS, patients with a negative troponin test had an overall
mortality between 0.7% (troponin I, cohort studies) and
2.1% (troponin I, trial studies). In patients with ECG
changes suggestive of ischemia, the short-term mortality
rates were higher, ranging from 1.6% (at 24 weeks) to 4.4%
(at 4 weeks). These results suggest that troponin test results
should be integrated with information from clinical history
and ECG results to identify low-risk patients.
Study limitations. Several limitations of our review should
be noted. Because there is no standard troponin I assay, we
could not compare threshold values across studies. In
addition, we could not determine which troponin I assay
was most predictive of outcome. The definition of unstable
angina varied across studies, which limited the ability to
compare results. Finally, potential under-reporting of neg-
ative studies may have increased the strength of the rela-
tionship between elevated troponin levels and outcome.
Conclusions. In summary, our study found that among
patients with possible cardiac ischemia or diagnosed unsta-
ble angina, an elevated troponin T or I indicates a signifi-
cantly higher short-term risk of cardiac events including
death and MI. The prognostic value of troponin was lower
in clinical trials than in cohort studies. Additional studies
enrolling consecutive patients (non-trial data) are needed to
determine the independent value of troponin data when
added to prognostic information from the history, physical
examination and ECG.
Figure 3. The association between the mortality rate for patients with an
initial negative troponin test (within 6 h of presentation) and the propor-
tion of patients in each study with electrocardiogram (ECG) evidence of
ischemia. The higher risk cohorts (more ECG ischemia) had a higher
mortality rate. Evidence of ischemia was defined separately for each trial
but usually consisted of ST depression or transient ST elevation. Data from
patients with persistent ST elevation are not included. Squares 5 negative
TnI (troponin I); circles 5 negative TnT (troponin T).
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